| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.42 | 1e-17 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.29 | 3e-15 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-12 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.23 | 4e-11 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.24 | 5e-11 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.32 | 2e-10 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-08 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.39 | 6e-06 |